ImmuCell (NASDAQ:ICCC) Shares Pass Above 200-Day Moving Average – Here’s What Happened

Shares of ImmuCell Corporation (NASDAQ:ICCC) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.11 and traded as high as $6.45. ImmuCell shares last traded at $6.44, with a volume of 2,936 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

ImmuCell Price Performance

The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. The business’s 50 day moving average price is $6.40 and its 200 day moving average price is $6.12.

Hedge Funds Weigh In On ImmuCell

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares in the last quarter. Steadtrust LLC purchased a new position in ImmuCell in the 3rd quarter valued at $198,000. Finally, Mesirow Financial Investment Management Inc. lifted its holdings in ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after purchasing an additional 24,303 shares in the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.